1. Home
  2. TVTX vs CCS Comparison

TVTX vs CCS Comparison

Compare TVTX & CCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TVTX
  • CCS
  • Stock Information
  • Founded
  • TVTX 2008
  • CCS 2000
  • Country
  • TVTX United States
  • CCS United States
  • Employees
  • TVTX N/A
  • CCS N/A
  • Industry
  • TVTX Biotechnology: Pharmaceutical Preparations
  • CCS Homebuilding
  • Sector
  • TVTX Health Care
  • CCS Consumer Discretionary
  • Exchange
  • TVTX Nasdaq
  • CCS Nasdaq
  • Market Cap
  • TVTX 1.4B
  • CCS 1.6B
  • IPO Year
  • TVTX N/A
  • CCS 2014
  • Fundamental
  • Price
  • TVTX $14.53
  • CCS $53.08
  • Analyst Decision
  • TVTX Strong Buy
  • CCS Buy
  • Analyst Count
  • TVTX 15
  • CCS 4
  • Target Price
  • TVTX $33.57
  • CCS $84.33
  • AVG Volume (30 Days)
  • TVTX 1.6M
  • CCS 425.5K
  • Earning Date
  • TVTX 07-31-2025
  • CCS 07-23-2025
  • Dividend Yield
  • TVTX N/A
  • CCS 2.22%
  • EPS Growth
  • TVTX N/A
  • CCS 7.67
  • EPS
  • TVTX N/A
  • CCS 9.70
  • Revenue
  • TVTX $273,533,000.00
  • CCS $4,352,977,000.00
  • Revenue This Year
  • TVTX $73.84
  • CCS N/A
  • Revenue Next Year
  • TVTX $46.72
  • CCS $4.98
  • P/E Ratio
  • TVTX N/A
  • CCS $5.40
  • Revenue Growth
  • TVTX 75.65
  • CCS 11.97
  • 52 Week Low
  • TVTX $6.80
  • CCS $50.42
  • 52 Week High
  • TVTX $25.29
  • CCS $108.42
  • Technical
  • Relative Strength Index (RSI)
  • TVTX 40.17
  • CCS 43.79
  • Support Level
  • TVTX $13.88
  • CCS $51.84
  • Resistance Level
  • TVTX $15.04
  • CCS $55.77
  • Average True Range (ATR)
  • TVTX 0.67
  • CCS 1.88
  • MACD
  • TVTX 0.04
  • CCS 0.09
  • Stochastic Oscillator
  • TVTX 36.93
  • CCS 26.91

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.

About CCS Century Communities Inc.

Century Communities Inc is engaged in the development, design, construction, marketing, and selling of single-family attached and detached homes. It has five homebuilding segments: West, Mountain, Texas, Southeast, and Century Complete. Its sixth reportable segment is financial services operations, which provides mortgage, title, and insurance services to homebuyers. It has acquired land for homebuilding operations with the primary intent to develop and construct single-family detached or attached homes for sale on the acquired land. The company sells homes through its sales representatives and independent real estate brokers. The company generates the majority of its revenue from the Mountain segment.

Share on Social Networks: